BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

159 related articles for article (PubMed ID: 38316717)

  • 21. Associations between primary tumor RAS, BRAF and PIK3CA mutation status and metastatic site in patients with chemo-resistant metastatic colorectal cancer.
    Christensen TD; Palshof JA; Larsen FO; Poulsen TS; Høgdall E; Pfeiffer P; Jensen BV; Yilmaz MK; Nielsen D
    Acta Oncol; 2018 Aug; 57(8):1057-1062. PubMed ID: 29380640
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Prevalence and coexistence of KRAS, BRAF, PIK3CA, NRAS, TP53, and APC mutations in Indian colorectal cancer patients: Next-generation sequencing-based cohort study.
    Jauhri M; Bhatnagar A; Gupta S; Bp M; Minhas S; Shokeen Y; Aggarwal S
    Tumour Biol; 2017 Feb; 39(2):1010428317692265. PubMed ID: 28222664
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Deleterious Effect of RAS and Evolutionary High-risk TP53 Double Mutation in Colorectal Liver Metastases.
    Chun YS; Passot G; Yamashita S; Nusrat M; Katsonis P; Loree JM; Conrad C; Tzeng CD; Xiao L; Aloia TA; Eng C; Kopetz SE; Lichtarge O; Vauthey JN
    Ann Surg; 2019 May; 269(5):917-923. PubMed ID: 28767562
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Ultra-selection of metastatic colorectal cancer patients using next-generation sequencing to improve clinical efficacy of anti-EGFR therapy.
    Vidal J; Bellosillo B; Santos Vivas C; García-Alfonso P; Carrato A; Cano MT; García-Carbonero R; Élez E; Losa F; Massutí B; Valladares-Ayerbes M; Viéitez JM; Manzano JL; Azuara D; Gallego J; Pairet S; Capellá G; Salazar R; Tabernero J; Aranda E; Montagut C
    Ann Oncol; 2019 Mar; 30(3):439-446. PubMed ID: 30689692
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Next-Generation Sequencing of Matched Primary and Metastatic Rectal Adenocarcinomas Demonstrates Minimal Mutation Gain and Concordance to Colonic Adenocarcinomas.
    Crumley SM; Pepper KL; Phan AT; Olsen RJ; Schwartz MR; Portier BP
    Arch Pathol Lab Med; 2016 Jun; 140(6):529-35. PubMed ID: 26536055
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Impact of KRAS, BRAF, PIK3CA, TP53 status and intraindividual mutation heterogeneity on outcome after liver resection for colorectal cancer metastases.
    Løes IM; Immervoll H; Sorbye H; Angelsen JH; Horn A; Knappskog S; Lønning PE
    Int J Cancer; 2016 Aug; 139(3):647-56. PubMed ID: 26991344
    [TBL] [Abstract][Full Text] [Related]  

  • 27. The Coexistence of RAS and BRAF Mutations in Metastatic Colorectal Cancer: A Case Report and Systematic Literature Review.
    Afrăsânie VA; Gafton B; Marinca MV; Alexa-Stratulat T; Miron L; Rusu C; Ivanov AV; Balan GG; Croitoru AE
    J Gastrointestin Liver Dis; 2020 Jun; 29(2):251-256. PubMed ID: 32530992
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Prognostic Impact of BRAF and KRAS Mutation in Patients with Colorectal and Appendiceal Peritoneal Metastases Scheduled for CRS and HIPEC.
    Graf W; Cashin PH; Ghanipour L; Enblad M; Botling J; Terman A; Birgisson H
    Ann Surg Oncol; 2020 Jan; 27(1):293-300. PubMed ID: 31571052
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Comparative analysis of primary tumour and matched metastases in colorectal cancer patients: evaluation of concordance between genomic and transcriptional profiles.
    Vignot S; Lefebvre C; Frampton GM; Meurice G; Yelensky R; Palmer G; Capron F; Lazar V; Hannoun L; Miller VA; André F; Stephens PJ; Soria JC; Spano JP
    Eur J Cancer; 2015 May; 51(7):791-9. PubMed ID: 25797355
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Genomic alterations accompanying tumour evolution in colorectal cancer: tracking the differences between primary tumours and synchronous liver metastases by whole-exome sequencing.
    Mogensen MB; Rossing M; Østrup O; Larsen PN; Heiberg Engel PJ; Jørgensen LN; Hogdall EV; Eriksen J; Ibsen P; Jess P; Grauslund M; Nielsen HJ; Nielsen FC; Vainer B; Osterlind K
    BMC Cancer; 2018 Jul; 18(1):752. PubMed ID: 30029640
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Mutational profiles and prognostic impact in colorectal and high-grade appendiceal adenocarcinoma with peritoneal metastases.
    Morgan RB; Dhiman A; Sood D; Ong CT; Wu X; Shergill A; Polite B; Turaga KK; Eng OS
    J Surg Oncol; 2023 Apr; 127(5):831-840. PubMed ID: 36636792
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Multi gene mutation signatures in colorectal cancer patients: predict for the diagnosis, pathological classification, staging and prognosis.
    Zhuang Y; Wang H; Jiang D; Li Y; Feng L; Tian C; Pu M; Wang X; Zhang J; Hu Y; Liu P
    BMC Cancer; 2021 Apr; 21(1):380. PubMed ID: 33836681
    [TBL] [Abstract][Full Text] [Related]  

  • 33. KRAS G12C Metastatic Colorectal Cancer: Specific Features of a New Emerging Target Population.
    Schirripa M; Nappo F; Cremolini C; Salvatore L; Rossini D; Bensi M; Businello G; Pietrantonio F; Randon G; Fucà G; Boccaccino A; Bergamo F; Lonardi S; Dei Tos AP; Fassan M; Loupakis F
    Clin Colorectal Cancer; 2020 Sep; 19(3):219-225. PubMed ID: 32605718
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Genetic Characteristics of Resectable Colorectal Cancer with Pulmonary Metastasis.
    Qiu YY; Peng D; Wei ZQ; Li JD; Huang YJ; Yang JG; Song ZY; Cheng Y
    Can J Gastroenterol Hepatol; 2022; 2022():2033876. PubMed ID: 35531124
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Integrated routine workflow using next-generation sequencing and a fully-automated platform for the detection of KRAS, NRAS and BRAF mutations in formalin-fixed paraffin embedded samples with poor DNA quality in patients with colorectal carcinoma.
    Franczak C; Dubouis L; Gilson P; Husson M; Rouyer M; Demange J; Leroux A; Merlin JL; Harlé A
    PLoS One; 2019; 14(2):e0212801. PubMed ID: 30811471
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Comprehensive tumor profiling reveals unique molecular differences between peritoneal metastases and primary colorectal adenocarcinoma.
    Stein MK; Williard FW; Xiu J; Tsao MW; Martin MG; Deschner BW; Dickson PV; Glazer ES; Yakoub D; Shibata D; Grothey AF; Philip PA; Hwang JJ; Shields AF; Marshall JL; Korn WM; Lenz HJ; Deneve JL
    J Surg Oncol; 2020 Jun; 121(8):1320-1328. PubMed ID: 32166754
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Impact of Single-organ Metastasis to the Liver or Lung and Genetic Mutation Status on Prognosis in Stage IV Colorectal Cancer.
    Cavallaro P; Bordeianou L; Stafford C; Clark J; Berger D; Cusack J; Kunitake H; Francone T; Ricciardi R
    Clin Colorectal Cancer; 2020 Mar; 19(1):e8-e17. PubMed ID: 31899147
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Comparison of neuroendocrine differentiation and KRAS/NRAS/BRAF/PIK3CA/TP53 mutation status in primary and metastatic colorectal cancer.
    Kleist B; Kempa M; Novy M; Oberkanins C; Xu L; Li G; Loland C; Poetsch M
    Int J Clin Exp Pathol; 2014; 7(9):5927-39. PubMed ID: 25337237
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Significance of RAS mutations in pulmonary metastases of patients with colorectal cancer.
    Igarashi T; Shimizu K; Usui K; Yokobori T; Ohtaki Y; Nakazawa S; Obayashi K; Yajima T; Nobusawa S; Ohkawa T; Katoh R; Motegi Y; Ogawa H; Harimoto N; Ichihara T; Mitani Y; Yokoo H; Mogi A; Shirabe K
    Int J Clin Oncol; 2020 Apr; 25(4):641-650. PubMed ID: 31773354
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Major challenges related to tumor biological characteristics in accurate mutation detection of colorectal cancer by next-generation sequencing.
    Li W; Qiu T; Guo L; Ying J
    Cancer Lett; 2017 Dec; 410():92-99. PubMed ID: 28942013
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 8.